Clinical Trial Update: tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancEr [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tailored decitabine repurposing for KRAS-dependent refractory pancreatic cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• Dacogen (decitabine)

Snippet

Sponsor: Luca Cardone | Conditions: Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma Recurrent | Phase 2 | Status: TERMINATED